Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study). Lancet 2000; 355: Sonia S Anand Question: Are oral anticoagulants (target INR 3.0-4.5) more effective than aspirin (80 mg) in the prevention of infrainguinal bypass-graft occlusion? Population: Patients who required infrainguinal bypass graft surgery (venous or synthetic grafts) for obstructive arterial disease. Design and methods: Randomized, open, clinical trial. A total of 1339 patients randomized to oral anticoagulants (target INR = 3.0-4.5) and 1351 to aspirin (80 mg/day). Treatment was started within 5 days of surgery. Primary outcome was graft occlusion defined as clinical examination and Doppler or duplex ultrasound evaluation and angiography when indicated. Mean length of follow-up was 21 months. Blinded adjudication of primary and secondary outcomes. Intention to treat analysis. Pre-specified subgroup analysis of primary outcome by graft type. Results: In all, 182/1326 (13.7%) discontinued oral anticoagulants and 190/1324 (14.3%) discontinued aspirin. A total of 308/1326 (23.2%) on oral anticoagulants vs 322/1324 (24.3%) on aspirin had graft occlusion; relative risk = 0.95 (95% CI: 0.82-1.11). Secondary outcome composite of cardiovascular death, myocardial infarction, stroke, and amputation was 248/1326 (18.7%) on oral anticoagulants vs 275/1324 (20.8%) on aspirin; relative risk = 0.89 (95% CI: 0.75-1.06). Major hemorrhage was 108/1326 (8.1%) on oral anticoagulants vs 56/1324 (4.2%) on aspirin; relative risk = 1.96 (95% CI: 1.42-2.71). For vein grafts (n = 1546) the relative risk of occlusion was 0.69 (95% CI: 0.54-0.88) on oral anticoagulants vs aspirin. For non-vein grafts (n = 1104) the relative risk of occlusion was 1.26 (95% CI: 1.03-1.55) on oral anticoagulants vs aspirin. The statistical test for interaction between these subgroups was significant (p = 0.002). Conclusion: High intensity warfarin (INR: 3-4.5) does not significantly reduce graft occlusion after infrainguinal bypass compared with aspirin. Oral anticoagulants are associated with a significant increase in major bleeding episodes. Oral anticoagulants and aspirin may alter the pathogenesis of graft re-occlusion differently depending on graft type.
Commentary
This well-conducted trial has helped to resolve some clinical dilemmas, but, as most studies do, it has raised new questions to be tested in future studies. The question of the role of oral anticoagulants in patients with peripheral arterial disease is long-standing and not yet completely resolved. Prior to this trial, studies have been generally small and hence their results conflicting. This trial provides convincing evidence that high-intensity oral anticoagulation on its own is not superior to aspirin in preventing graft occlusion.
However, perhaps more important than graft occlusion in peripheral arterial disease patients is the high risk of nonfatal and fatal myocardial infarction and stroke they suffer over the long-term. While oral anticoagulants appeared to reduce these events compared with aspirin, the relative differences were small and non-significant. Any benefit of oral anticoagulants must be offset by both the 'hassle factor' and the increased risk of bleeding that accompanies their use. In this study, the small margin of benefit observed with © Arnold 2001 1358-863X(01)VM360XX oral anticoagulants was offset by the increased risk of major hemorrhage that oral anticoagulants confer (relative risk = 1.96, p Ͻ0.001).
A pre-specified subgroup analysis raised the questions of whether oral anticoagulants are more effective than aspirin in preventing graft occlusion in patients with vein grafts, and whether aspirin is more effective than oral anticoagulation in preventing graft occlusion in patients with synthetic grafts. These findings suggest but do not prove that the pathogenesis of graft occlusion in synthetic grafts is more of a platelet-dependent process compared with reocclusion of vein grafts. This intriguing hypothesis must be tested prospectively.
Vascular viewpoint rating:
• Randomized-large • High-quality • Is the primary conclusion valid? -most likely.
